Navigation Links
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Date:10/28/2008

cal and research objectives, and we are very pleased to bring Linda Hogan on board. Linda is a skilled and accomplished business development professional who is able to draw on a breadth of experience at Care Capital and Clearview to help advance CoLucid's partnering initiatives."

"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."

CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for t
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
4. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
5. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
6. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
7. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
11. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay ... 40th birthday without ever tying the knot, since research has ... folks. And, um, isn,t there something wrong with those who ... new study looking at psychological measures shows that never-married people ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
(Date:12/5/2009)... to do everything from growing mushrooms, making wine to keeping prisoners in ... ... that your wine, water and vegetables would have come from Wind Turbines? ... turbines, for industry end users, not wind farms. "Using a technology ...
(Date:12/4/2009)... YORK, Dec. 4 Care Investment Trust Inc. (NYSE: ... its Board of Directors has declared a dividend of $0.17 per ... 22, 2009 to common shareholders of record on December 14, 2009. ... Care Investment Trust Inc. is a real estate investment and finance ...
(Date:12/4/2009)... Dec. 4 Medithrive, Inc. has won the Patient,s ... Bay Area by popular vote conducted by the online ... operation, the SF Bay community has selected Medithrive as ... ,, The rapid rise and popularity of Medithrive confirms ...
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... Pharmacyclics,Inc. (Nasdaq: PCYC ) today announced that ... and Drug Administration (FDA) for the company,s,new drug application ... non-small cell lung cancer (NSCLC) patients with brain,metastases. The ... brain,radiation therapy (WBRT) was filed with the FDA in ...
... Corp. ("Echo" or the "Company") (OTC Bulletin Board: ... meeting of stockholders today,that the polls will remain ... vote on the proposed merger transaction with XLNT,Veterinary ... forth in the,proxy statement/prospectus previously mailed to Echo ...
... Inc. (Nasdaq:,BIOD) today announced that Dr. Solomon Steiner, Chairman ... the 26th Annual JPMorgan Healthcare,Conference on Monday, January 7, ... Healthcare Conference will be held January 7-10, 2008, at,the ... Interested parties may access a link to a live ...
... HORSHAM, Pa. and KENILWORTH, N.J., Dec. 21 ... SGP ) today announced,they have revised their ... distribution of both REMICADE(R),(infliximab), an anti-tumor necrosis ... and golimumab, Centocor,s next-generation,human, anti-TNF alpha therapy, ...
... Alta Bates Summit Medical Center receives shipment milestone ... SET and Masimo Rainbow SET technologies, IRVINE, ... of Pulse CO-Oximetry and Read-Through Motion and Low,Perfusion ... shipped its,500,000th Masimo SET bedside pulse oximeter (excluding ...
... ensure consumers, interests are considered, protected, HARRISBURG, Pa., ... protected, acting Insurance Commissioner Joel,Ario today announced that the ... of its review of the proposed consolidation of,Independence Blue ... to see that consumers would be protected in,any transaction ...
Other Medicine News:Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 2Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 3Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 4Health News:Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to December 28, 2007 5Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 2Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 3Health News:Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2
(Date:12/4/2009)... U.S. Food and Drug Administration (FDA) today approved Zyprexa® ... treatment of schizophrenia and manic or mixed episodes associated ... old. ,, The updated Zyprexa label states that ... weight gain and hyperlipidemia in adolescents compared to adults ...
(Date:12/4/2009)... ,, PHILADELPHIA, Dec. 4 Teamster members employed by ... hard at work educating the public about the unfair ... Philadelphia,s blood supply at risk. More than 100 ... line yesterday when their issues were ignored by their ...
(Date:12/4/2009)... Inc. (OTC Bulletin Board: OXBT) today announced that the ... II-b, dose escalation, clinical trial in Switzerland for use ... is the Company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ,, ... outcome of patients with severe TBI. We hope to ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 1Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 3Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 1Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 2Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 3Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 5Fish vision discovery makes waves in natural selection 10401 1Fish vision discovery makes waves in natural selection 10401 2Fish vision discovery makes waves in natural selection 10401 3
... 10, 2007 - Inotek,Pharmaceuticals Corporation announced today the ... showing that the,administration of a poly(ADP-Ribose) polymerase (PARP) ... of certain brain,cells following a stroke. PARP is ... DNA via the activation and recruitment of DNA,repair ...
... Unite to Help Educate on Good,Diabetes Management and ... Problems, SEATTLE, April 10, 2007 /PRNewswire/ -- A ... type 2 diabetes,complications shows that an estimated three ... diabetes have at least one of the other,serious ...
Other Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
... reagents for the quantitative determination of ... as well as heparin- and EDTA- ... using the BN Systems. In acute ... number of plasma proteins, including C-reactive ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: